August 31, 2021
Eli Lilly Japan and Daiichi Sankyo said on August 30 that they have forged another migraine drug collaboration in Japan, after one for Emgality (galcanezumab) launched in April. The latest deal covers Lilly’s lasmiditan succinate, which is currently pending Japanese...read more